what would you tell week-1 you about dose escalation
The title is the whole question — what would you tell week-1 you about dose escalation — but here is why I am asking. It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it. The standing caveat,…
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
research-use-only material is not approved for human use, full stop
research-use-only material is not approved for human use, full stop
Agreed, and the glucagon arm is exactly why the comparison threads do not work.
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.
nothing here is available as a prescription product, so read every thread with that in mind
a lot of the confident posting here is extrapolation
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.